Investment firm Omega has significantly increased its eighth biotech fund to $647 million, nearing the size of its prior fund. This fundraising success signals continued investor appetite and confidence in biotech innovation pipelines. The upsizing from the initial target reflects robust capital availability to fuel cutting-edge biotech ventures amid an evolving funding landscape.